LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

Home・Aandelen Lijst・Ascendis Pharma A-S ADR

Ascendis Pharma A-S ADR

Gesloten

SectorGezondheidszorg

215.17 -1.26

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

213.19

Max

216.59

Belangrijke statistieken
By Trading Economics
Inkomsten	-22M -61M
Verkoop	56M 214M
Winstmarge	-28.549
Werknemers	1,017
EBITDA	-56M -53M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+31.78% upside

Dividenden
By Dow Jones
Volgende Winsten	30 apr 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	1.7B 14B
Vorige openingsprijs	216.43
Vorige sluitingsprijs	215.17

Nieuwssentiment

By Acuity

54%

46%

283 / 352 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

157.66 / 167.29 Steun & Weerstand

Ascendis Pharma A-S ADR Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

13 feb 2026, 16:32 UTC

Winsten

Enbridge, TC Energy Investing in Opportunities to Tap Rising Energy Demand, Boom in Data Centers -- Update

14 feb 2026, 22:02 UTC

Winsten

Looking for Dividends? Consider Europe. -- Barrons.com

14 feb 2026, 09:20 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

13 feb 2026, 21:57 UTC

Winsten

Stocks Rise on Softer Inflation Data, but AI Jitters Trigger Worst Week Since November -- WSJ

13 feb 2026, 21:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

13 feb 2026, 21:20 UTC

Winsten

Applied Materials, Rivian, Moderna, Arista, Fastly, Coinbase, Robinhood, DraftKings, and More Stock Market Movers -- Barrons.com

13 feb 2026, 21:05 UTC

Acquisities, Fusies, Overnames

Constellation Software: Lumine Group Completes Acquisition of Synchronoss Technologies >CSU.T SNCR

13 feb 2026, 20:45 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

13 feb 2026, 20:45 UTC

Marktinformatie

Dollar Pares Down Early Losses -- Market Talk

13 feb 2026, 20:39 UTC

Marktinformatie

Potential for Mild Winter Ahead Sinks Natural Gas for Week -- Market Talk

13 feb 2026, 20:28 UTC

Marktinformatie

Oil Settles Week Lower -- Market Talk

13 feb 2026, 19:51 UTC

Winsten

These Stocks Are Today's Movers: Applied Materials, Rivian, Moderna, Arista, Fastly, Coinbase, Robinhood, DraftKings, and More -- Barrons.com

13 feb 2026, 19:32 UTC

Marktinformatie

Gold and Silver Climb to Finish Week In Positive Territory -- Market Talk

13 feb 2026, 19:32 UTC

Marktinformatie

Gold and Silver Climb to Finish Week In Positive Territory -- Market Talk

13 feb 2026, 19:29 UTC

Winsten

Big Tech's Spending Spree Could Limit Buybacks and Dividends -- Barrons.com

13 feb 2026, 18:18 UTC

Acquisities, Fusies, Overnames

Exxon, Walmart and 9 Other Stocks That Are Soaring Because Cash Is King Again -- Barrons.com

13 feb 2026, 17:52 UTC

Winsten

Pinterest's Earnings Give More Proof of Meta Platform's Dominance -- Barrons.com

13 feb 2026, 17:16 UTC

Winsten

These Stocks Are Today's Movers: Applied Materials, Rivian, Moderna, Arista, Fastly, Coinbase, Robinhood, DraftKings, and More -- Barrons.com

13 feb 2026, 17:10 UTC

Acquisities, Fusies, Overnames

Vibe-Coding in Gas Town? A Guide to the Software Selloff With 4 Sexy Stock Picks. -- Barrons.com

13 feb 2026, 16:59 UTC

Winsten

AppLovin Stock Stabilizes After Selloff. Its Biggest Critic Waves the White Flag. -- Barrons.com

13 feb 2026, 16:39 UTC

Acquisities, Fusies, Overnames

Berkshire Might Have Sold More Apple, Bank of America Stock in Fourth Quarter -- Barrons.com

13 feb 2026, 16:11 UTC

Winsten

Nvidia Stock Wobbles. The Focus Is Turning to Earnings. -- Barrons.com

13 feb 2026, 16:07 UTC

Marktinformatie

Hungarian Forint Could Rise Further -- Market Talk

13 feb 2026, 15:54 UTC

Winsten

Detroit Automakers Take $50 Billion Hit as EV Bubble Bursts -- WSJ

13 feb 2026, 15:26 UTC

Marktinformatie

Indian Imports of Saudi Crude Hit Highest Since 2022 -- Market Talk

13 feb 2026, 15:01 UTC

Winsten

These Stocks Are Today's Movers: Applied Materials, Rivian, Moderna, Steel Dynamics, Coinbase, DraftKings, Tri Pointe Homes, and More -- Barrons.com

13 feb 2026, 15:00 UTC

Winsten

Expedia Falls, but Airbnb Rises. Why Online Travel Stocks Face a Tough Year. -- Barrons.com

13 feb 2026, 14:50 UTC

Marktinformatie

Oil Moves Lower As Market Weighs Geopolitical Risk -- Market Talk

13 feb 2026, 14:44 UTC

Winsten

Arista Networks Stock Climbs. Why It Is Outshining Cisco. -- Barrons.com

13 feb 2026, 14:22 UTC

Marktinformatie

Winsten

Global Energy Roundup: Market Talk

Peer Vergelijking

Prijswijziging

Ascendis Pharma A-S ADR Prognose

Koersdoel

By TipRanks

31.78% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 287.42 USD 31.78%

Hoogste 342 USD

Laagste 250 USD

Gebaseerd op 12 Wall Street-analisten die 12-maands prijsdoelen bieden voor Ascendis Pharma A-S ADR - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

12 ratings

Buy

Hold

Sell

Gebaseerd op 12 analisten die aandelenratings hebben gegeven aan Ascendis Pharma A-S ADR - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

157.66 / 167.29Steun & Weerstand

Recent bearish events outweigh bullish events.

Bullish events outweigh bearish events.

All events are bullish.

Sentiment

By Acuity

283 / 352 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Ascendis Pharma A-S ADR

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.